Consensus on MRD in AML?

Elisabeth Paietta

doi:10.1182/blood-2018-01-828145

Consensus on MRD in AML?

Elisabeth Paietta

Medicine

Research output: Contribution to journal › Comment/debate › peer-review

17 Scopus citations

Abstract

The European LeukemiaNet (ELN) Working Party publishes its consensus document on minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) in this issue of Blood; Schuurhuis et al’s article reports the status of existing methodologies for MRD assessments, provides guidelines for standardized approaches, and recommends future directions.

Original language	English (US)
Pages (from-to)	1265-1266
Number of pages	2
Journal	Blood
Volume	131
Issue number	12
DOIs	https://doi.org/10.1182/blood-2018-01-828145
State	Published - Mar 22 2018

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2018-01-828145

Fingerprint Dive into the research topics of 'Consensus on MRD in AML?'. Together they form a unique fingerprint.

Cite this

@article{b0ef3f911532431fa42a9b363ec4c05f,

title = "Consensus on MRD in AML?",

abstract = "The European LeukemiaNet (ELN) Working Party publishes its consensus document on minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) in this issue of Blood; Schuurhuis et al{\textquoteright}s article reports the status of existing methodologies for MRD assessments, provides guidelines for standardized approaches, and recommends future directions.",

author = "Elisabeth Paietta",

year = "2018",

month = mar,

day = "22",

doi = "10.1182/blood-2018-01-828145",

language = "English (US)",

volume = "131",

pages = "1265--1266",

journal = "Blood",

issn = "0006-4971",